What's Happening?
Researchers at The University of Texas MD Anderson Cancer Center have identified a molecular pathway that explains how aging cells contribute to the formation of unstable atherosclerotic plaques, potentially leading to heart attacks and strokes. The study
found that the loss of regulatory proteins LATS1/2 in senescent cells activates the CD38 enzyme, causing inflammation and increasing the risk of blood clot formation. This discovery provides insight into the mechanisms behind plaque instability and could inform new therapeutic strategies to prevent cardiovascular events.
Why It's Important?
The findings offer a new understanding of how cellular aging affects cardiovascular health, particularly in the context of atherosclerosis. This research could lead to the development of targeted therapies to stabilize plaques and reduce the risk of heart attacks and strokes. Additionally, the study highlights potential cardiovascular side effects of cancer treatments that accelerate cellular aging, emphasizing the need for comprehensive patient care strategies. The discovery of the CD38 pathway opens avenues for exploring existing CD38 inhibitors as potential treatments for cardiovascular conditions.
What's Next?
Further research is needed to explore potential biomarkers and therapeutic targets related to the CD38 pathway. Clinical trials may be conducted to assess the efficacy of CD38 inhibitors in stabilizing plaques and preventing thrombosis. The study's findings could lead to the repurposing of existing CD38 inhibitors, already approved for other conditions, to address cardiovascular risks. Continued investigation into the molecular mechanisms of aging cells will be crucial for developing effective interventions.
